Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it will release its fourth quarter and year-end 2021 financial results on March 3, 2022, at 7:30 a.m. ET, followed by a conference call at 8:45 a.m. ET. The company focuses on developing therapeutics for viral diseases, including ongoing clinical trials for its lead compound, AB-729, targeting Hepatitis B virus. A live webcast will be available on Arbutus' investor website, and an archived version will be accessible after the event.
- Scheduled release of Q4 and year-end 2021 financial results indicating transparency and ongoing investor communication.
- Ongoing development of AB-729, which shows promise in clinical trials for chronic Hepatitis B.
- None.
WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2021 financial results and corporate update for Thursday, March 3, 2022. The schedule for the press release and conference call/webcast are as follows:
| • | Q4 and Year End 2021 Press Release: | March 3, 2022 at 7:30 a.m. ET |
| • | Q4 and Year End 2021 Conference Call/Webcast: | March 3, 2022 at 8:45 a.m. ET |
| • | Domestic Dial-In Number: | (866) 393-1607 |
| • | International Dial-In Number: | (914) 495-8556 |
| • | Conference ID Number: | 3977368 |
A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 3977368.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV) and coronaviruses. In HBV, we are developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that we intend to combine to improve the outcomes of patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. Our lead compound, AB-729 is the only RNAi therapeutic with evidence of immune re-awakening and is currently being evaluated in multiple phase 2 clinical trials. We have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including COVID-19). We are also exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
FAQ
When will Arbutus Biopharma announce its Q4 and year-end 2021 financial results?
What time is the conference call for Arbutus Biopharma's Q4 2021 results?
What is the conference ID number for the Arbutus Biopharma call?
How can I access the webcast for Arbutus Biopharma's conference call?
What is AB-729 and its significance for Arbutus Biopharma?
